Clinical trial
A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias
NCT00406029 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 20, 2006
- Completion date
- November 3, 2008
- Enrollment
- 253 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.